| Abstract |
[Abstract] Objective: To compare the efficacy, safety and social function of palmitic acid (pp1m) injection and olanzapine tablets in the treatment of schizophrenia. Methods: 100 schizophrenics patients who were hospitalized from August 2021 to December 2022 were selected. The control group was divided into 50 patients with olanzapine, 50 patients in the study group were treated with PPIM injection, and the total incidence of adverse reactions were compared. Results: the reduction rate of PANSS in the study group was higher than that of the control group, and the SDSS score of the study group was lower than that of the control group after 1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks and 12 weeks after treatment, and the difference was statistically significant (P < 0.05). The PSP score of the study group was higher than that of the control group after 1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks and 12 weeks, and PRL in the study group was higher than that of the control group (P < 0.05). PBG in the study group was compared with the control group (P > 0.05). The total incidence of adverse reactions in the study group (8.00%) was compared with that of the control group (10.00%), P>0.05. Conclusion: PPIM injection can effectively improve the clinical symptoms and social function of schizophrenics, and the incidence of adverse reactions is low, but it will cause the increase of prolactin. Therefore, the monitoring of prolactin should be strengthened in the treatment of schizophrenia patients.
|